Business Wire

The 26th Neuronal Plasticity Prize of the Fondation Ipsen has been awarded to

Share

The 26th Neuronal Plasticity Prize of the Fondation Ipsen has been awarded to three scientists for their pioneering work in the domain of genes, synapses and psychiatric disorders: Mark F. Bear (Massachusetts Institute of Technology, Cambridge, USA), David J. Porteous (University of Edinburgh, Edinburgh, UK) and Thomas Bourgeron (Institut Pasteur - CNRS, Paris, France). The prize has been awarded on July 8th, 2015 at the IBRO World Congress (International Brain Research Organisation) in Rio de Janeiro by an international jury led by Nikos Logothetis (Max Planck Institute for Biological Cybernetics, Tübingen, Germany).

About the laureates

Mark F. Bear is an Investigator of the Howard Hughes Medical Institute, and Picower Professor of Neuroscience in The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology. Dr. Bear served as Director of The Picower Institute from 2007 to 2009. Prior to moving to MIT in 2003, Dr. Bear was on the faculty of Brown University School of Medicine for 17 years. After receiving his B.S. degree from Duke University, he earned his Ph.D. degree in neurobiology at Brown. He took postdoctoral training from Wolf Singer at the Max Planck Institute for Brain Research in Frankfurt, Germany, and from Leon Cooper at Brown. Bear’s laboratory has substantially advanced knowledge of how cerebral cortex is modified by experience. He made fundamental discoveries on bidirectional synaptic plasticity, metaplasticity, the molecular basis of amblyopia (a cause of visual disability in children), and the pathophysiology of fragile X syndrome (the most common inherited cause of intellectual disability and autism). He has been at the forefront of the efforts to translate knowledge of autism pathophysiology into new treatments.

David J. Porteous is Chair of Human Molecular Genetics and Medicine at the Institute of Genetics and Molecular Medicine (www. igmm.ed.ac.uk ), Edinburgh, a world ‘top 20’ University. He is a Fellow of the Royal Society of Edinburgh, the Royal College of Physicians (Edinburgh), the Academy of Medical Sciences and EMBO. In 2013, he was awarded the OBE for contributions to science by the Queen. For over 20 years, he has used genetics and genomics to identify genes that determine the risk of developing mental illness, most notably the discovery of the DISC1 gene in 2000. This work established a new paradigm in psychiatric genetics of ‘one gene, several disorders’ and is now recognized as one of the most informative findings in the field (Science Magazine Breakthrough of the Year, 2005). In 2003, he established Generation Scotland, a cohort of 24,000 participants in 7,000 family groups who have been examined for a wide range of medically relevant traits, including personality, mood and mental health. He is now investigating the genetic and environment factors that determine risk and resilience to major depression disorder as a first step towards predictive and precision medicine.

Thomas Bourgeron has started his research career investigating mitochondria first in plant and then in neurological diseases, he moved to the Institut Pasteur in Paris to pursue his interests in the genetics of autism spectrum disorder (ASD). In 2003, his group published the first mutations associated with ASD linking genes and synapses to this complex condition. In 2008, he became Professor at the University Paris Diderot and Director of the Unit on Human Genetics and Cognitive Functions in the Neuroscience Department of the Institut Pasteur. In 2014 he has been elected at the French Académie des Sciences. His group includes geneticists, neurobiologists and clinicians to study the genetic susceptibility to ASD. Their present research is focused on the genetic architecture of ASD. They are combining whole genome sequencing technologies with original phenotyping approaches using brain imaging, biochemistry, induced pluripotent stem cells (iPSC) as well as clinical evaluations of the patients. This multidisciplinary group aims to provide knowledge-based discoveries for a better diagnostic, care and integration of individuals with ASD.

About the Neuronal Plasticity Prize

Founded in 1990, the Neuronal Plasticity Prize of La Fondation Ipsen has been awarded to renowned specialists: Albert Aguayo (Montréal, 1990), Anders Björklund (Lund, 1990), Fred Gage (La Jolla, 1990), Ursula Bellugi (La Jolla, 1991), Wolf Singer (Frankfurt, 1990), Torsten Wiesel (New York, 1991), Philippe Ascher (Paris, 1992), Kjell Fuxe (Stockholm, 1992), Terje Lomo (Oslo, 1992), Per Andersen (Oslo, 1993), Masao Ito (Wako Saitama, 1993), Constantino Sotelo (Paris, 1993), Mariano Barbacid (Princeton, 1994), Yves Barde (Planegg-Martinsried, 1994), Hans Thoenen (Planegg-Martinsried, 1994), Jacques Mehler (Paris, 1995), Brenda Milner (Montreal, 1995), Mortimer Mishkin (Bethesda, 1995), Friedrich Bonhoeffer (Tubingen, 1996), Corey Goodman (Berkeley, 1996), Marc Tessier-Lavigne (San Francisco, 1996), Antonio Damasio (Iowa City, 1997), Richard Frackowiac (London, 1997), Michael Merzenich (San Francisco, 1997), Heinrich Betz (Frankfurt, 1998), Gerald Fischbach (Boston, 1998), Uel McMahan (Stanford, 1998), Masakazu Konishi (Pasadena, 1999), Peter Marler (Davis, 1999), Fernando Nottebohm (Millbrook, 1999), Tomas Hökfelt (Stockholm, 2000), Lars Olson (Stockholm, 2000), Lars Terenius (Stockholm, 2000), Albert Galaburda (Boston, 2001), John Morton (Londres, 2001), Elisabeth Spelke (Cambridge, USA, 2001), Arturo Alvarez-Buylla (San Francisco, 2002), Ronald Mc Kay (Bethesda, 2002), Sam Weiss (Calgary, 2002), François Clarac (Marseille, 2003), Sven Grillner (Stockholm, 2003), Serge Rossignol (Montréal, 2003), James Gusella (Boston, 2004), Jean-Louis Mandel (Strasbourg, 2004), Huda Y. Zoghbi (Houston, 2004), Ann Graybiel (Cambridge, USA, 2005), Trevor Robbins (Cambridge, UK, 2005), Wolfram Schultz (Cambridge, UK, 2005, Eckhart D. Gundelfinger (Magdeburg, 2006), Mary B. Kennedy (Pasadena, 2006), Morgan Sheng (Cambridge, USA, 2006), Nikos K. Logothetis (Tübingen, 2007), Keiji Tanaka (Wako, 2007), Giacomo Rizzolati (Parma, 2007), Jean-Pierre Changeux (Paris, 2008), Peter W. Kalivas (Charleston 2008), Eric J. Nestler (Dallas, 2008), Alim-Louis Benabid (Grenoble, 2009), Apostolos P. Georgopoulos (Minneapolis, 2009) , Miguel A. L. Nicolelis (Durham, 2009), Thomas Insel (Bethesda, 2010), Bruce Mc Ewen (New York, 2010), Donald Pfaff (New York, 2010), Helen Neville (Eugene, 2011), Isabelle Peretz (Montreal, 2011), Robert Zatorre (Montreal, 2011), Catherine Dulac (Boston, 2012), Richard G. Morris (Edinburgh, 2012), J. David Sweatt (Birmingham, 2012), Tim V.P. Bliss (London, 2013), Richard G. M. Morris (Edinburgh, 2013), Yadin Dudai (Rehovot, 2013), Barry J. Everitt (Cambridge, UK, 2014), George F. Koob (La Jolla, 2014) and Michel Le Moal (Bordeaux, 2014).

The jury: Nikos Logothetis (Max-Planck Institute for Biological Cybernetics, Tübingen, Germany) President, Alim-Louis Benabid (CEA, CHU de Grenoble, Inserm, Université Joseph Fourier, Grenoble, France), Joël Bockaert (CNRS UMR 5203, Montpellier, France), Alexis Brice (CRICM UMRS 975 - Hôpital de la Pitié Salpêtrière, Paris, France), Yves Christen (Fondation IPSEN, Paris, France), Stanislas Dehaene (Centre NeuroSpin, CEA/SAC/DSV/I2BM, Gif-sur-Yvette, France), Kjell Fuxe (Karolinska Institutet, Stockholm, Sweden), Fred Gage (Salk Institute for Biological Studies, La Jolla, USA), Ann Graybiel (Massachusetts Institute of Technology, Cambridge, USA), Wolf Singer (Max-Planck Institute for Brain Research, Frankfurt, Germany).

About the Fondation Ipsen

Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. The long-standing action of the Fondation Ipsen aims at fostering the interaction between researchers and clinical practitioners, which is indispensable due to the extreme specialization of these professions. The ambition of the Fondation Ipsen is to initiate a reflection about the major scientific issues of the forthcoming years. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to six main themes: Alzheimer's disease, neurosciences, longevity, endocrinology, the vascular system and cancer science. Moreover the Fondation Ipsen has started since 2007 several meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the Days of Molecular Medicine Global Foundation as well as with the science journals Nature, Cell and Science. The Fondation Ipsen produced several hundred publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.
www.fondation-ipsen.org

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Isabelle de Segonzac, Image Sept
E-mail : isegonzac@image7.fr
Tel. : +33 (0)1 53 70 74 70

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global CIOs geared up to scale AI but organizations aren’t as ready25.4.2024 05:00:00 CEST | Press release

AI is the CIO’s top priority, according to findings of Lenovo’s third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by speed, security, and other organizational functions lagging in AI readiness. In a stark contrast to previous years, CIOs are tabling non-traditional responsibilities to sharpen their focus on core IT functions. Slightly more than half (51%) of CIOs feel AI/ML is an urgent priority to address, matched only by cybersecurity. This urgency is directly correlated to the pressure that CIOs are under to drive business impact, rather than operational maintenance and preservation. 84% of CIOs revealed they are being evaluated on business outcome metrics more than ever before. “Today’s CIOs are working in a tornado of innovation. After years of IT expanding into non-traditional responsibilities, we’re now seeing how AI is forcing CIOs back to their

Mundipharma acquires all assets and rights related to REZZAYO ® (rezafungin) , reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 22:01:00 CEST | Press release

Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafunginis a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune systemand the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inclu

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting24.4.2024 22:01:00 CEST | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year’s ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that address the unmet needs of patients with B-cell malignancies and solid tumors,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “The exciting data we will share during ASCO showcase BRUKINSA’s uniquely differentiated clinical profile and add to the growing body of evidence supporting its role across the blood cancer treatment paradigm.” BeiGene will share new data for BRUKINSA (zanubrutinib), which add to the robust efficacy and safety evidence differentiating it within the BTK class. Key highlights include: A network meta-analysis co

TSMC Celebrates 30 th North America Technology Symposium with Innovations Powering AI with Silicon Leadership24.4.2024 21:30:00 CEST | Press release

TSMC (TWSE: 2330, NYSE: TSM) today unveiled its newest semiconductor process, advanced packaging, and 3D IC technologies for powering the next generation of AI innovations with silicon leadership at the Company’s 2024 North America Technology Symposium. TSMC debuted the TSMC A16TM technology, featuring leading nanosheet transistors with innovative backside power rail solution for production in 2026, bringing greatly improved logic density and performance. TSMC also introduced its System-on-Wafer (TSMC-SoW™) technology, an innovative solution to bring revolutionary performance to the wafer level in addressing the future AI requirements for hyperscaler datacenters. This year marks the 30th anniversary of TSMC’s North America Technology Symposium, and more than 2,000 attended the event, growing from less than 100 attendees 30 years ago. The North America Technology Symposium in Santa Clara, California kicks off TSMC Technology Symposiums around the world in the coming months. The symposiu

Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer24.4.2024 18:50:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the appointment of Steve Hershkowitz as its new Chief Revenue Officer (CRO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424061249/en/ Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer (Photo: Business Wire) “Steve’s leadership and extensive experience scaling businesses to deliver top-line growth will expand our sales reach to capture new logos and increase our opportunity to provide even greater value to our clients,” said Rimini Street president and CEO Seth Ravin. “The global revenue team and I are excited to work closely together with Steve to drive growth and broader capabilities for our company.” Leading the Next Chapter of Sales Growth and Continued Success f

HiddenA line styled icon from Orion Icon Library.Eye